Breakthrough trial aims to replace toxic treatment for deadly fungal infection
NCT ID NCT06525389
Summary
This large Phase 3 trial aims to find safer and more effective treatments for talaromycosis, a serious fungal infection that is a leading cause of death in people with advanced HIV in Southeast Asia. It will test if a single strong dose of a newer, less toxic drug works better than the current two-week toxic treatment, and if adding a second drug improves outcomes. The study also explores a new strategy for deciding when to stop preventive medication after recovery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TALAROMYCOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bach Mai Hospital
Hanoi, Vietnam
Contact Email: •••••@•••••
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital for Tropical Diseases
Ho Chi Minh City, 7000, Vietnam
Contact
-
National Hospital for Tropical Diseases
Hanoi, Vietnam
Contact
-
Pham Ngoc Thach University of Medicine
Ho Chi Minh City, 7000, Vietnam
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.